Janssen picks up AC Immune's Alzheimer's vaccine

AC Immune has signed a license agreement with Johnson and Johnson subsidiary Janssen, worth a potential $509m, to develop its Alzheimer's disease vaccine candidates.

More from Neurological

More from Therapy Areas